Media coverage about Repligen Corporation (NASDAQ:RGEN) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Repligen Corporation earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 48.9937421795619 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

Repligen Corporation (NASDAQ:RGEN) traded up 0.27% during midday trading on Friday, reaching $41.18. 217,812 shares of the company’s stock traded hands. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81. The firm has a market cap of $1.54 billion, a PE ratio of 80.59 and a beta of 1.30. The firm’s 50-day moving average is $41.91 and its 200 day moving average is $36.63.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.16 earnings per share. Equities research analysts expect that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Saturday. First Analysis restated an “equal weight” rating and issued a $40.00 target price on shares of Repligen Corporation in a report on Friday, April 21st. Jefferies Group LLC restated a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Finally, William Blair assumed coverage on shares of Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $42.00.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with's FREE daily email newsletter.